Logo

Health

As a total healthcare enterprise, the Otsuka group of companies creates innovative products and seeks ways to maintain and promote better health for all.

Addressing Unmet Needs

The Otsuka group is passionate about its philosophy to contribute to better health for people worldwide, and it does by striving to create groundbreaking new products of a kind that only Otsuka can conceive.

Addressing Unmet Needs

Theme thumb otsuka pic12

Otsuka Pharmaceutical

Theme thumb otsuka pic11

Taiho Pharmaceutical

Theme thumb otsuka pic13

Otsuka Pharmaceutical Factory

Diseases of the central nervous system include schizophrenia, depression, bipolar disorder, and Alzheimer’s disease. The underlying causes of these diseases have yet to be precisely elucidated, making the research and development of treatments extremely challenging. Cures remain elusive, while expectations from patients and their families for new, better drugs remain high.  Otsuka Pharmaceutical began research into central nervous system diseases in the 1970s, which ultimately led to the US launch of ABILIFY, an antipsychotic and the first-ever dopamine partial antagonist, in 2002. The drug has been used to benefit the lives of patients in approximately 60 countries and regions worldwide. CNS diseases and their treatments are often accompanied by adherence issues: patients may lack an understanding of their condition, dislike the side effects of their medication and stop taking it, or forget to take it. This often leads to disease relapses. For better patient outcomes and improved adherence, in 2013 Otsuka Pharmaceutical launched ABILIFY MAINTENA, a prolonged-release version of ABILIFY administered as a once-monthly, intramuscular injection. Additionally, as a new treatment option, the company first launched REXULTI, an antipsychotic with a new mechanism of action in the US in 2015. Otsuka Pharmaceutical also acquired Avanir Pharmaceuticals in 2015. This US company developed NUEDEXTA, the first-ever treatment approved specifically for pseudobulbar affect (PBA*). Acquiring Avanir Pharmaceuticals has enabled Otsuka to expand its therapeutic reach in the neurologic area and complement its extensive capabilities in psychiatric diseases.
In the area of oncology, Otsuka is focusing on blood cancers, developing and commercializing ICLUSIG to treat patients with chronic myeloid leukemia in ten Asian markets including Japan. Additionally, in the areas of cardio-renal disease and nephrology, the company developed Samsca, the first-ever treatment to slow the progression of autosomal dominant polycystic kidney disease (ADPKD), a genetic disease in which numerous cysts develop in both kidneys. (Samsca is marketed outside Japan for ADPKD under the brand name JINARC.)
In the area of infectious diseases, Otsuka is focused on tuberculosis, a critical public health issue worldwide. The company introduced the anti-tuberculosis drug DELTYBA in Europe and Japan in 2014.
Otsuka Pharmaceutical received two Commendations for Science and Technology (Development Category) by the Minister of Education, Culture, Sports, Science and Technology in 2016 in recognition of Otsuka's discovery and development of delamanid (DELTYBA) one of the first new anti-TB drugs in almost five decades, and for tolvaptan (Samsca/JINARC), an antagonist of the vasopressin V2 receptor.

Taiho Pharmaceutical is one of Japan’s foremost creators of anticancer agents, with over 40 years of experience in chemotherapies. Taiho Pharmaceutical pioneered oral anticancer formulations before they became common worldwide. In 1974, the company introduced the oral anticancer agent Futraful, and has since brought to market UFT (in 1984), TS-1 (in 1999), and LONSURF (in 2014). The company strives to meet patients’ needs in the area of oncology, including new formulations (UFT in capsules and enteric granules; and TS-1 in capsules, granules, and orally disintegrating tablets) and development of UZEL (in 2003) with the aim of strengthening the efficacy of UFT in treating colorectal cancer. These oral formulations are recommended in medical guidelines for a number of different cancers.
Recommended under treatment guidelines in Europe and North America, LONSURF, a treatment for refractory metastatic colorectal cancer, is expected to help improve the treatment of cancer worldwide. The company also continues its global clinical development of new products. While there has been enormous recent progress in cancer treatment, significant unmet medical needs remain. Following its development in Japan, in 2015 Taiho Pharmaceutical launched Yondelis, a treatment for soft tissue sarcoma that is recommended in European and North American medical guidelines. The company also is committed to developing treatments for rare cancers in cases where unmet medical needs are deep. With the patient’s perspective in mind, the Otsuka group is committed to research and development on new anticancer drugs that will be integral in future cancer treatments and that will help with supportive care, such as antiemetic agents and drugs to alleviate cancer pain.

Otsuka Pharmaceutical Factory undertakes research and development with a global frame of reference, prioritizing clinical nutrition, surgical products, and regenerative medicine with the aim of creating new value. In the area of clinical nutrition, the company used its pioneering IV container technology to develop an antibiotics kit that enables antibiotics and solvents to be prepared in a sterile environment with a single press, as well as Elneopa Injection No. 1 and No. 2, high-calorie, total parenteral nutrition solutions containing glucose, electrolytes, amino acids, multiple vitamins, and trace elements in the first-ever, quad-chamber bag. These revolutionary new products help improve convenience and prevent medical errors. In 2017, Otsuka Pharmaceutical Factory launched Elneopa NF Injection No. 1 and No. 2, new formulas developed on the basis of prescriptions written outside Japan where Elneopa is widely used. In addition to working on improvements of existing products, the company also focuses on research into next-generation clinical nutrition products with treatment applications. Otsuka Pharmaceutical Factory is also engaged in the development of surgical products. In 2015, the company launched Olanedine, the first new topical antiseptic solution to be approved in Japan in 50 years, and has accelerated research expected to lead to the development of next-generation products to help prevent infectious diseases and post-surgery complications. Otsuka Pharmaceutical Factory engages in regenerative medicine research in both the US and Japan. The company focuses on bioartificial pancreas islets, an area that shows promise as a more effective method of type 1 diabetes treatment, as well as research intended to help create highly functional products that will enable a wide range of hospitals and clinics to provide cellular treatment. In addition to these priority areas, Otsuka Pharmaceutical Factory has also established project teams for the purpose of creating revolutionary new drugs. In order to create the products that patients truly need, the company is committed to listening to patients and healthcare professionals from the earliest stages to identify issues that could emerge in the future, and consequently develop a flexible approach that is not confined to existing frameworks.

* Pseudobulbar affect (PBA) is a neurological disorder in which individuals cannot control their feelings or actions. It is characterized by involuntary outbursts of crying in front of others and laughing in inappropriate situations.
 

VOICE

写真
Advancing Preventive Medicine
Yasuhide Inoue Senior Manager, Perioperative Medicine Research Office, Naruto Research Institute
Otsuka Pharmaceutical Factory, Inc.
 

It has long been said that it is important to prevent illness. This is called preventive medicine. As part of Otsuka Pharmaceutical Factory’s contribution to preventive medicine, we created the first new antiseptic in Japan in 50 years, Olanedine, which was launched in September 2015. Confirmed as extremely effective in sterilizing against methicillin-resistant Staphylococcus aureus (MRSA) infections, which are resistant to conventional antiseptics, and against vancomycin-resistant enterococci (VRE), this agent is expected to help prevent new in-hospital infections.

Otsuka Pharmaceutical, Otsuka Pharmaceutical Factory, Taiho Pharmaceutical

Global Initiatives for Public Health

Theme thumb img fightback

FIGHTBACK photobooks were published by Otsuka in collaboration with various local organizations to raise awareness of TB—a disease that is forgotten, but far from gone. The photobooks feature encouraging stories of patients who have fought against TB with the help of doctors, nurses, families and friends.

Multidrug-resistant tuberculosis (MDR-TB)*1, TB that is resistant to at least two of the most commonly used first-line anti-tuberculosis medications, is an increasing public health issue. After a long period of research and development, DELTYBA (delamanid), a treatment for adult pulmonary MDR-TB, was approved initially in the EU, Japan, and South Korea in 2014. The drug is one of the first new anti-TB medications to be approved in almost 50 years. In 2016, Otsuka entered into an agreement with the Stop TB Partnership’s*2 Global Drug Facility (GDF), enabling distribution of DELTYBA to over 100 low-and middle-income countries. In addition to drug access, training and technical support is provided to ensure the drug is used correctly and effectively incorporated into existing TB treatment programs.

*1 When TB bacteria become resistant to at least the two most commonly used first-line medicines, isoniazid and rifampicin, the infection is called multidrug-resistant (MDR).
*2 Established in 2001 with the aim of eradicating tuberculosis. Participants include international organizations such as the WHO, government agencies, private enterprises, and patient groups. The Global Drug Facility was created as a subsidiary organization of the Stop TB Partnership to increase access to high-quality and affordable TB treatments and diagnostics.
Otsuka Pharmaceutical

Addressing Yet-to-be-imagined Consumer Needs

Theme thumb  img 7755 %e5%b7%ae%e3%81%97%e6%9b%bf%e3%81%88170707

Otsuka Pharmaceutical: Saga Nutraceuticals Research Institute

Theme thumb img labo02

Otsuka Pharmaceutical: Otsu Nutraceuticals Research Institute

In the area of nutraceuticals, Otsuka Pharmaceuticals leverages its medical-related expertise to develop original functional foods, beverages and other scientifically-based products to maintain and promote the health of people around the world. The company’s perseverance in communicating the value of these functional products has created an unprecedented new market. Today, Japan and many other developed countries face a number of issues, including extended healthy life expectancies, aging populations, declining birthrates, and the increasing burden of medical expenses, which lead the company to focus on yet-to-be-imagined needs in the areas of exercise and nutrition, and women’s health.
In 1980, the company launched POCARI SWEAT, a health drink that replenishes water and electrolytes lost to sweat. Since the product’s launch over 30 years ago, Otsuka Pharmaceutical Saga Nutraceuticals Research Institute has continued to conduct research on electrolyte and fluid replacement. The company conveys the importance of hydration, including electrolytes, and provides support in a variety of situations such as playing sports, at workplaces and for the elderly. Educational events at sports venues have helped ensure that proper hydration is an essential component of athletes’ training regimens.
In 2016, the company launched POCARI SWEAT JELLY, an edible form of hydration, to appeal to those who fail to hydrate despite understanding the need to sufficiently hydrate.
In 2017, the company launched BODYMAINTÉ JELLY, which is targeted at athletes undertaking rigorous daily training who are at risk of losing their peak condition and anxious about conditioning before competition. Formulated specifically to prevent deterioration in physical condition under rigorous training regimens, the company developed and combined lactic acid B240*1, a unique Otsuka Pharmaceutical ingredient for maintaining physical function, as well as whey protein and BCAA*2 +Arginine for physical conditioning.
Our involvement in the maintenance and improvement of health extends beyond athletes to all consumers concerned about maintaining their day-to-day health. In 2016, Otsuka Pharmaceutical joined with the Japan Sport Council (JSC) High Performance Center to launch a collaborative research project between industry, government and academia to advance sports medicine and science to boost Japan’s international competitiveness. The knowledge gained from this research will be used to develop guidelines for sports conditioning that will serve as 'soft legacy' beyond 2020, informing educational activities for maintaining and improving the health of the general population.
With regard to women’s health, Otsuka Pharmaceutical launched EQUELLE, a food product containing equol, in 2014. Having explored the various possibilities of soybeans for decades, the company discovered in its research on the isoflavones contained in soybeans that equol, an ingredient derived through intestinal bacteria from soybean isoflavones, is closely tied to women’s health. Otsuka researchers identified Lactococcus 20-92, a lactic acid bacteria that produces equol when fermented on soybean germ. Following these discoveries, the company launched EQUELLE containing equol, which helps women stay healthy and beautiful during and after the midlife transitional period when they experience various physical and mental changes. Otsuka’s Saga Nutraceuticals Research Institute and Kindai University also released the results of joint research on this topic in 2016. The company will continue researching solutions for women’s health issues and ways to improve women’s quality of life.

*1 Lactic acid B240 was isolated by Tokyo University of Agriculture and confirmed for efficacy by Otsuka Pharmaceutical.
*2 BCAA: Branched Chain Amino Acid (three amino acids: valine, leucine, and isoleucine)
Otsuka Pharmaceutical

Medical Food Research from a Global Perspective

Theme thumb %e3%83%8f%e3%82%a4%e3%83%8d%e3%82%a4%e3%83%bc%e3%82%b2%e3%83%ab

Otsuka Pharmaceutical Factory: HINE E-GEL, one of the concentrated liquid nutrition series

Theme thumb img foods02

Otsuka Pharmaceutical Factory: ENGELEAD for people who experience difficulty swallowing

Theme thumb  o0q4440

Otsuka Pharmaceutical Factory: Taste testing Otsuka food products

Otsuka Pharmaceutical Factory, a pharmaceutical company with a strong foundation in clinical nutrition, leverages this expertise in its mission to develop original, scientifically-backed food products. These medical food products find applications in healthcare and nursing care settings. With our social responsibilities in mind, as a pharmaceutical company in a super-aging society, we have accelerated product development in Japan based on three areas: dehydration, malnutrition, and dysphagia (difficulty swallowing).
For example, OS-1, an oral rehydration solution, addresses oral rehydration therapy advocated by the WHO (World Health Organization) and is the first food for special dietary uses approved in Japan for people with mild to moderate dehydration. Another product approved as a Food for Special Dietary Uses, ENGELEAD, was developed specifically for those who experience difficulty swallowing. The company has also expanded its HINE series of concentrated liquid nutrition, adding products such as HINE E-GEL, a digestive type with a new consistency. The company is actively working to expand its line of medical foods and bring these revolutionary products to markets in other countries in Asia and elsewhere.
Otsuka Pharmaceutical Factory

Support Ranging from IV Solutions to Eating Solid Food

Theme thumb img foods

EN Otsuka Pharmaceutical: “iEat” Chikuzen-ni

Theme thumb %e3%82%ad%e3%83%bc%e3%83%9e%e3%82%ab%e3%83%ac%e3%83%bc

Otsuka Foods: “My Size: line! Plus” Keema Curry

Otsuka Pharmaceutical Factory develops products that comprehensively support the nutritional management of patients throughout their convalescence from the acute to the recovery phase. These range from the company’s core IV solution products and enteral nutrition products to medical foods to make patients more comfortable. In IV solutions, the company strives to develop revolutionary products that meet the needs of patients and healthcare professionals, such as the first-ever IV solution quad bag, which provides greater convenience and helps prevent mistakes in preparation.
EN Otsuka Pharmaceutical has responded to the increasing number of elderly and sick patients who have difficulty in eating regular food, yet desire to eat solid food, rather than conventional purees and finely chopped foods. The company’s iEat series helps patients recover their ability to eat by offering nutritious foods that retain the look and taste of the food patients are used to eating, but are soft enough to break down in the mouth with just the tongue. These products are used in home nursing situations, as well as in nursing homes, hospitals and other facilities.
In 2010, Otsuka Foods launched its My Size series of retort food products prepared to be just the right size. Carefully prepared curry ingredients and rice bowl toppings, packaged rice, and portion control are features that ensure these popular products provide delicious meals with an easy-to-understand 100 or 150 kilocalories per serving. In 2016, the company launched its My Size: line! Plus series of products sold exclusively in Japanese pharmacies. The series is designed for people concerned not only about calories, but also their intake of salt, proteins, and sugars. As opportunities for health management and nutrition guidance campaigns increase at regular prescription drug pharmacies in Japan, and the Japanese government moves to create a system of Health Support Pharmacies, the My Size: line! Plus series is gaining the attention of consumers looking for products to support a healthy diet.

VOICE

写真
Providing Information and Expanding Product Lines based on the Interrelationships between Medical and Dental Care
Kenichi Ogasawara Chief of a Division Product Planning Division,
Operating Officer
EN Otsuka Pharmaceutical Co., Ltd.
 

Today there is increasing focus on the relationship between oral and overall physical health. An oral cavity or poor nutrition can cause various illnesses and degrade bodily functions. For example, maintaining good oral hygiene can be effective in preventing aspiration pneumonia. Promoting greater collaboration between the medical and dental fields is therefore a matter of some urgency. EN Otsuka Pharmaceutical has developed and launched the REFRECARE series of oral care products. We also manufacture and market iEat, a series of products that support the ability to eat and provide nutrition to help patients who have difficulty eating recover their ability to enjoy the solid food they used to eat. We also manufacture and market RACOL-NF Semi Solid for Enteral Use, RACOL-NF Liquid for Enteral Use and Twinline-NF Liquid for Enteral Use. These are prescription drug enteral nutrition formulas that can be administered directly into the stomach or intestine in a relatively short period of time, giving patients more time for rehabilitation. We will continue to add new products to this line and raise awareness at academic conferences to do what we can to promote collaboration between the medical and dental industries, provide appropriate information, and manufacture products that meet healthcare needs.

Otsuka Pharmaceutical Factory, EN Otsuka Pharmaceutical, Otsuka Foods
Health
Addressing Unmet Needs
Response thumb otsuka pic12

Addressing Unmet Needs

Diseases of the central nervous system include schizophrenia, depression, b...

Health
Addressing Unmet Needs
Response thumb img fightback

Global Initiatives for Public Health

Multidrug-resistant tuberculosis (MDR-TB)*1, TB that is resistant to at lea...

Health
Addressing Unmet Needs
Response thumb  img 7755 %e5%b7%ae%e3%81%97%e6%9b%bf%e3%81%88170707

Addressing Yet-to-be-imagined Consumer Needs

In the area of nutraceuticals, Otsuka Pharmaceuticals leverages its medical...

Health
Addressing Unmet Needs
Response thumb %e3%83%8f%e3%82%a4%e3%83%8d%e3%82%a4%e3%83%bc%e3%82%b2%e3%83%ab

Medical Food Research from a Global Perspective

Otsuka Pharmaceutical Factory, a pharmaceutical company with a strong found...

Health
Addressing Unmet Needs
Response thumb img foods

Support Ranging from IV Solutions to Eating Solid Food

Otsuka Pharmaceutical Factory develops products that comprehensively suppor...

Health
Raising Awareness of Health
Response thumb %e5%a4%a7%e5%a1%9a%e8%a3%bd%e8%96%ac %e7%86%b1%e4%b8%ad%e7%97%87%e4%ba%88%e9%98%b2%e5%95%93%e7%99%ba%e6%b4%bb%e5%8b%95

Building Awareness of Prevention of Heat Disorders

Ever since the launch of POCARI SWEAT, Otsuka Pharmaceutical has been advoc...

Health
Raising Awareness of Health
Response thumb img womanhelth01

Raising Awareness of Women’s Health

The average lifespan in Japan, which is over 80 years old for both men and ...

Health
Raising Awareness of Health
Response thumb %e5%a4%a7%e9%b5%ac%e8%96%ac%e5%93%81 %e3%83%94%e3%83%b3%e3%82%af%e3%83%aa%e3%83%9c%e3%83%b3%e3%82%b7%e3%83%b3%e3%83%9d%e3%82%b8%e3%82%a6%e3%83%a0%e3%81%ab%e3%81%a6%e3%81%8c%e3%82%93%e3%81%ae%e6%a4%9c%e8%a8%ba%e5%95%93%e7%99%ba%e3%83%84%e3%83%bc%e3%83%ab%e3%82%92%e9%85%8d%e5%b8%83

Supporting the Pink Ribbon Campaign

Taiho Pharmaceutical supports the Pink Ribbon campaign, a worldwide effort ...

Health
Communicating Health Information
Response thumb %e5%a4%a7%e9%b5%ac%e8%96%ac%e5%93%81 survivorship.jp

Health Information Online

Otsuka group companies are involved in awareness-building activities to pro...

Health
Communicating Health Information
Response thumb %e5%a4%a7%e5%a1%9a%e9%a3%9f%e5%93%81

My First Water Project

Otsuka Foods has been running the My First Water Project, which aims to dis...

Health
Communicating Health Information
Response thumb %e5%86%8a%e5%ad%90%ef%be%97%ef%bd%b2%ef%be%9d%ef%be%85%ef%bd%af%ef%be%8c%ef%be%9f

Otsuka Health Comic Library

The Otsuka group has been publishing the Otsuka Health Comic Library since ...

Health
Communicating Health Information
Response thumb img twenty

20 – TWENTY

Taiho Pharmaceutical provides support for the National Cancer Center Hospit...

Health
Communicating Health Information
Response thumb %e7%b5%b1%e5%90%88%e5%a4%b1%e8%aa%bf%e7%97%87%e3%83%95%e3%82%a9%e3%83%bc%e3%83%a9%e3%83%a0img 1136

Raising Awareness about Illness

Since 2009, Otsuka Pharmaceutical has provided support for forums on schizo...